GMAB Genmab A/S
USHealthcareAs of 2026-07-09 16:00
Why GMAB matters now
Genmab A/S (GMAB) is a US stock in Healthcare. The latest InvestLog snapshot shows $29.78 with +0.81% on the session and $18.28B in market capitalization; recent performance reads 1-month -1.60% and YTD -17.95%.
The latest financial table shown here is Q1 2026, with revenue of $899.3M, net income of $53.2M, and EPS of $0.08. Investors can compare that operating picture with valuation signals such as P/E 6.33 and FCF yield 5.7%.
The latest indexable market news headline is "EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $40.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
6.33
PEG
—
P/B
2.72
P/S
1.64
EV/EBITDA
13.65
DCF Value
$6.20
FCF Yield
5.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
38.7%
Operating Margin
13.7%
Net Margin
8.7%
ROE
14.5%
ROA
6.6%
ROIC
8.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $899.3M | $53.2M | $0.08 |
| Q4 2025 | $1.05B | $30.9M | $0.05 |
| FY 2025 | $3.72B | $963.8M | $1.54 |
| Q3 2025 | $1.02B | $401.0M | $0.65 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$38.30
Target (Median)
$40.00
Target Range
$32.00 - $41.50
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
DK
Exchange
—
Beta
0.68
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.